{"id":"https://openalex.org/W3203612698","doi":"https://doi.org/10.3389/fphar.2021.743582","title":"Pulmonary Toxicities Associated With the Use of Immune Checkpoint Inhibitors: An Update From the Immuno-Oncology Subgroup of the Neutropenia, Infection & Myelosuppression Study Group of the Multinational Association for Supportive Care in Cancer","display_name":"Pulmonary Toxicities Associated With the Use of Immune Checkpoint Inhibitors: An Update From the Immuno-Oncology Subgroup of the Neutropenia, Infection & Myelosuppression Study Group of the Multinational Association for Supportive Care in Cancer","publication_year":2021,"publication_date":"2021-10-05","ids":{"openalex":"https://openalex.org/W3203612698","doi":"https://doi.org/10.3389/fphar.2021.743582","mag":"3203612698","pmid":"https://pubmed.ncbi.nlm.nih.gov/34675810","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/8523897"},"language":"en","primary_location":{"id":"doi:10.3389/fphar.2021.743582","doi":"https://doi.org/10.3389/fphar.2021.743582","is_oa":true,"landing_page_url":"https://doi.org/10.3389/fphar.2021.743582","pdf_url":"https://www.frontiersin.org/articles/10.3389/fphar.2021.743582/pdf","source":{"id":"https://openalex.org/S132108250","display_name":"Frontiers in Pharmacology","issn_l":"1663-9812","issn":["1663-9812"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","ki-jl-1","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320527","host_organization_name":"Frontiers Media","host_organization_lineage":["https://openalex.org/P4310320527"],"host_organization_lineage_names":["Frontiers Media"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Frontiers in Pharmacology","raw_type":"journal-article"},"volume":null,"type":"review","is_traditional":true,"indexed_in":["crossref","datacite","doaj","pubmed"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://www.frontiersin.org/articles/10.3389/fphar.2021.743582/pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5043177871","display_name":"Bernardo Leon Rapoport","orcid":"https://orcid.org/0000-0001-7610-3653","observed_orcids":["https://orcid.org/0000-0001-7610-3653"]},"institutions":[{"id":"https://openalex.org/I4210089752","display_name":"The Medical Oncology Centre of Rosebank","ror":"https://ror.org/00cpjch55","country_code":"ZA","type":"healthcare","lineage":["https://openalex.org/I4210089752"]},{"id":"https://openalex.org/I4405273230","display_name":"Multinational Association of Supportive Care in Cancer","ror":"https://ror.org/05gs8za89","country_code":"CA","type":"nonprofit","lineage":["https://openalex.org/I4405273230"]},{"id":"https://openalex.org/I69552723","display_name":"University of Pretoria","ror":"https://ror.org/00g0p6g84","country_code":"ZA","type":"education","lineage":["https://openalex.org/I69552723"]}],"countries":["CA","ZA"],"is_corresponding":true,"raw_author_name":"Bernardo L. Rapoport","raw_affiliation_strings":["Department of Immunology, Faculty of Health Sciences, University of Pretoria, Pretoria, South Africa","The Medical Oncology Centre of Rosebank, Johannesburg, South Africa","The Multinational Association for Supportive Care in Cancer (MASCC), Immuno-Oncology Subgroup of the Neutropenia, Infection and Myelosuppression Study Group, Manchester, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Immunology, Faculty of Health Sciences, University of Pretoria, Pretoria, South Africa","institution_ids":["https://openalex.org/I69552723"]},{"raw_affiliation_string":"The Medical Oncology Centre of Rosebank, Johannesburg, South Africa","institution_ids":["https://openalex.org/I4210089752"]},{"raw_affiliation_string":"The Multinational Association for Supportive Care in Cancer (MASCC), Immuno-Oncology Subgroup of the Neutropenia, Infection and Myelosuppression Study Group, Manchester, United Kingdom","institution_ids":["https://openalex.org/I4405273230"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5013644953","display_name":"Vickie R. Shannon","orcid":"https://orcid.org/0000-0002-5938-4841","observed_orcids":["https://orcid.org/0000-0002-5938-4841"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Vickie R. Shannon","raw_affiliation_strings":["Department of Pulmonary Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Pulmonary Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, United States","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5044960572","display_name":"Tim Cooksley","orcid":"https://orcid.org/0000-0001-6114-1956","observed_orcids":["https://orcid.org/0000-0001-6114-1956"]},"institutions":[{"id":"https://openalex.org/I28407311","display_name":"University of Manchester","ror":"https://ror.org/027m9bs27","country_code":"GB","type":"education","lineage":["https://openalex.org/I28407311"]},{"id":"https://openalex.org/I4210092852","display_name":"Manchester University NHS Foundation Trust","ror":"https://ror.org/00he80998","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I4210092852"]},{"id":"https://openalex.org/I4405273230","display_name":"Multinational Association of Supportive Care in Cancer","ror":"https://ror.org/05gs8za89","country_code":"CA","type":"nonprofit","lineage":["https://openalex.org/I4405273230"]}],"countries":["CA","GB"],"is_corresponding":false,"raw_author_name":"Tim Cooksley","raw_affiliation_strings":["Manchester University Foundation Trust, Manchester, United Kingdom","The Christie, University of Manchester, Manchester, United Kingdom","The Multinational Association for Supportive Care in Cancer (MASCC), Immuno-Oncology Subgroup of the Neutropenia, Infection and Myelosuppression Study Group, Manchester, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Manchester University Foundation Trust, Manchester, United Kingdom","institution_ids":["https://openalex.org/I4210092852"]},{"raw_affiliation_string":"The Christie, University of Manchester, Manchester, United Kingdom","institution_ids":["https://openalex.org/I28407311"]},{"raw_affiliation_string":"The Multinational Association for Supportive Care in Cancer (MASCC), Immuno-Oncology Subgroup of the Neutropenia, Infection and Myelosuppression Study Group, Manchester, United Kingdom","institution_ids":["https://openalex.org/I4405273230"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5025067315","display_name":"Douglas Buckner Johnson","orcid":"https://orcid.org/0000-0002-6390-773X","observed_orcids":["https://orcid.org/0000-0002-6390-773X"]},"institutions":[{"id":"https://openalex.org/I200719446","display_name":"Vanderbilt University","ror":"https://ror.org/02vm5rt34","country_code":"US","type":"education","lineage":["https://openalex.org/I200719446"]},{"id":"https://openalex.org/I4390039299","display_name":"Vanderbilt-Ingram Cancer Center","ror":"https://ror.org/02rjj2m04","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210162197","https://openalex.org/I4390039299","https://openalex.org/I901861585"]},{"id":"https://openalex.org/I901861585","display_name":"Vanderbilt University Medical Center","ror":"https://ror.org/05dq2gs74","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210162197","https://openalex.org/I901861585"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Douglas B. Johnson","raw_affiliation_strings":["Department of Medicine, Vanderbilt University Medical Centre and Vanderbilt Ingram Cancer Center, Nashville, TN, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medicine, Vanderbilt University Medical Centre and Vanderbilt Ingram Cancer Center, Nashville, TN, United States","institution_ids":["https://openalex.org/I200719446","https://openalex.org/I4390039299","https://openalex.org/I901861585"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Lindsay Anderson","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2802675445","display_name":"Steve Biko Hospital","ror":"https://ror.org/015gtm372","country_code":"ZA","type":"healthcare","lineage":["https://openalex.org/I2802675445"]},{"id":"https://openalex.org/I69552723","display_name":"University of Pretoria","ror":"https://ror.org/00g0p6g84","country_code":"ZA","type":"education","lineage":["https://openalex.org/I69552723"]}],"countries":["ZA"],"is_corresponding":false,"raw_author_name":"Lindsay Anderson","raw_affiliation_strings":["Department of Radiation Oncology, Steve Biko Academic Hospital, Faculty of Health Sciences, University of Pretoria, Pretoria, South Africa"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Radiation Oncology, Steve Biko Academic Hospital, Faculty of Health Sciences, University of Pretoria, Pretoria, South Africa","institution_ids":["https://openalex.org/I2802675445","https://openalex.org/I69552723"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5068707033","display_name":"Ada Gabriela Blidner","orcid":"https://orcid.org/0000-0002-1092-3656","observed_orcids":["https://orcid.org/0000-0002-1092-3656"]},"institutions":[{"id":"https://openalex.org/I151201029","display_name":"Consejo Nacional de Investigaciones Cient\u00edficas y T\u00e9cnicas","ror":"https://ror.org/03cqe8w59","country_code":"AR","type":"government","lineage":["https://openalex.org/I151201029","https://openalex.org/I4210123736","https://openalex.org/I4387155568"]},{"id":"https://openalex.org/I71650599","display_name":"Experimental Medicine and Biology Institute","ror":"https://ror.org/03hnwy706","country_code":"AR","type":"facility","lineage":["https://openalex.org/I151201029","https://openalex.org/I4210123736","https://openalex.org/I4387155568","https://openalex.org/I71650599"]}],"countries":["AR"],"is_corresponding":false,"raw_author_name":"Ada G. Blidner","raw_affiliation_strings":["Laboratory of Immunopathology, Institute of Biology and Experimental Medicine, CONICET, Buenos Aires, Argentina"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Laboratory of Immunopathology, Institute of Biology and Experimental Medicine, CONICET, Buenos Aires, Argentina","institution_ids":["https://openalex.org/I151201029","https://openalex.org/I71650599"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111529537","display_name":"Gregory R. Tintinger","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2802675445","display_name":"Steve Biko Hospital","ror":"https://ror.org/015gtm372","country_code":"ZA","type":"healthcare","lineage":["https://openalex.org/I2802675445"]},{"id":"https://openalex.org/I69552723","display_name":"University of Pretoria","ror":"https://ror.org/00g0p6g84","country_code":"ZA","type":"education","lineage":["https://openalex.org/I69552723"]}],"countries":["ZA"],"is_corresponding":false,"raw_author_name":"Gregory R. Tintinger","raw_affiliation_strings":["Department of Internal Medicine, Steve Biko Academic Hospital, Faculty of Health Sciences, University of Pretoria, Pretoria, South Africa"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Internal Medicine, Steve Biko Academic Hospital, Faculty of Health Sciences, University of Pretoria, Pretoria, South Africa","institution_ids":["https://openalex.org/I2802675445","https://openalex.org/I69552723"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5030988903","display_name":"Ronald Anderson","orcid":"https://orcid.org/0000-0002-5925-6452","observed_orcids":["https://orcid.org/0000-0002-5925-6452"]},"institutions":[{"id":"https://openalex.org/I4405273230","display_name":"Multinational Association of Supportive Care in Cancer","ror":"https://ror.org/05gs8za89","country_code":"CA","type":"nonprofit","lineage":["https://openalex.org/I4405273230"]},{"id":"https://openalex.org/I69552723","display_name":"University of Pretoria","ror":"https://ror.org/00g0p6g84","country_code":"ZA","type":"education","lineage":["https://openalex.org/I69552723"]}],"countries":["CA","ZA"],"is_corresponding":false,"raw_author_name":"Ronald Anderson","raw_affiliation_strings":["Department of Immunology, Faculty of Health Sciences, University of Pretoria, Pretoria, South Africa","The Multinational Association for Supportive Care in Cancer (MASCC), Immuno-Oncology Subgroup of the Neutropenia, Infection and Myelosuppression Study Group, Manchester, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Immunology, Faculty of Health Sciences, University of Pretoria, Pretoria, South Africa","institution_ids":["https://openalex.org/I69552723"]},{"raw_affiliation_string":"The Multinational Association for Supportive Care in Cancer (MASCC), Immuno-Oncology Subgroup of the Neutropenia, Infection and Myelosuppression Study Group, Manchester, United Kingdom","institution_ids":["https://openalex.org/I4405273230"]}]}],"institutions":[],"countries_distinct_count":5,"institutions_distinct_count":12,"corresponding_author_ids":["https://openalex.org/A5043177871"],"corresponding_institution_ids":["https://openalex.org/I4210089752","https://openalex.org/I4405273230","https://openalex.org/I69552723"],"apc_list":{"value":2950,"currency":"USD","value_usd":2950},"apc_paid":{"value":2950,"currency":"USD","value_usd":2950},"fwci":0.7591,"has_fulltext":true,"cited_by_count":42,"citation_normalized_percentile":{"value":0.6551883,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":95,"max":99},"biblio":{"volume":"12","issue":null,"first_page":"743582","last_page":"743582"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T14072","display_name":"Immunotoxicology and immune responses","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10870","display_name":"Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/immune-checkpoint-inhibitors","display_name":"immune checkpoint inhibitors","score":0.996999979019165},{"id":"https://openalex.org/keywords/immune-related-adverse-events","display_name":"immune-related adverse events","score":0.8339999914169312},{"id":"https://openalex.org/keywords/immune-checkpoint-inhibitor-pneumonitis","display_name":"immune checkpoint inhibitor pneumonitis","score":0.9210000038146973},{"id":"https://openalex.org/keywords/pulmonary-toxicity","display_name":"pulmonary toxicity","score":0.8510000109672546},{"id":"https://openalex.org/keywords/pd-1-inhibitors","display_name":"PD-1 inhibitors","score":0.7749999761581421},{"id":"https://openalex.org/keywords/pd-l1-inhibitors","display_name":"PD-L1 inhibitors","score":0.9980000257492065},{"id":"https://openalex.org/keywords/ctla-4-inhibitors","display_name":"CTLA-4 inhibitors","score":0.9750000238418579},{"id":"https://openalex.org/keywords/regulatory-t-cells","display_name":"regulatory T cells","score":0.9779999852180481},{"id":"https://openalex.org/keywords/immune-dysregulation","display_name":"immune dysregulation","score":0.8700000047683716},{"id":"https://openalex.org/keywords/thoracic-radiotherapy","display_name":"thoracic radiotherapy","score":0.7289999723434448},{"id":"https://openalex.org/keywords/nivolumab","display_name":"nivolumab","score":0.781000018119812},{"id":"https://openalex.org/keywords/pembrolizumab","display_name":"pembrolizumab","score":0.9929999709129333},{"id":"https://openalex.org/keywords/durvalumab","display_name":"durvalumab","score":0.8870000243186951},{"id":"https://openalex.org/keywords/avelumab","display_name":"avelumab","score":0.925000011920929},{"id":"https://openalex.org/keywords/atezolizumab","display_name":"atezolizumab","score":0.9480000138282776},{"id":"https://openalex.org/keywords/cemiplimab","display_name":"cemiplimab","score":0.7160000205039978},{"id":"https://openalex.org/keywords/pathogenesis","display_name":"pathogenesis","score":0.5870000123977661},{"id":"https://openalex.org/keywords/diagnosis","display_name":"diagnosis","score":0.800000011920929}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8030896782875061},{"id":"https://openalex.org/C2775949291","wikidata":"https://www.wikidata.org/wiki/Q20707748","display_name":"Atezolizumab","level":5,"score":0.6800771951675415},{"id":"https://openalex.org/C2777742743","wikidata":"https://www.wikidata.org/wiki/Q19904005","display_name":"Durvalumab","level":5,"score":0.6792752742767334},{"id":"https://openalex.org/C2780030458","wikidata":"https://www.wikidata.org/wiki/Q7041828","display_name":"Nivolumab","level":4,"score":0.6649398803710938},{"id":"https://openalex.org/C2781433595","wikidata":"https://www.wikidata.org/wiki/Q2459042","display_name":"Ipilimumab","level":4,"score":0.6560869216918945},{"id":"https://openalex.org/C2779524853","wikidata":"https://www.wikidata.org/wiki/Q1284347","display_name":"Pneumonitis","level":3,"score":0.6010160446166992},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.5116575360298157},{"id":"https://openalex.org/C2777381376","wikidata":"https://www.wikidata.org/wiki/Q21083261","display_name":"Avelumab","level":5,"score":0.5057680606842041},{"id":"https://openalex.org/C2776256026","wikidata":"https://www.wikidata.org/wiki/Q47912","display_name":"Lung cancer","level":2,"score":0.478452205657959},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.4413054585456848},{"id":"https://openalex.org/C2780057760","wikidata":"https://www.wikidata.org/wiki/Q13896859","display_name":"Pembrolizumab","level":4,"score":0.4319721460342407},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.3981536626815796},{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.3892055153846741},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.3776547908782959},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.35390520095825195},{"id":"https://openalex.org/C2777714996","wikidata":"https://www.wikidata.org/wiki/Q7886","display_name":"Lung","level":2,"score":0.15067815780639648}],"mesh":[],"locations_count":7,"locations":[{"id":"doi:10.3389/fphar.2021.743582","doi":"https://doi.org/10.3389/fphar.2021.743582","is_oa":true,"landing_page_url":"https://doi.org/10.3389/fphar.2021.743582","pdf_url":"https://www.frontiersin.org/articles/10.3389/fphar.2021.743582/pdf","source":{"id":"https://openalex.org/S132108250","display_name":"Frontiers in Pharmacology","issn_l":"1663-9812","issn":["1663-9812"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","ki-jl-1","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320527","host_organization_name":"Frontiers Media","host_organization_lineage":["https://openalex.org/P4310320527"],"host_organization_lineage_names":["Frontiers Media"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Frontiers in Pharmacology","raw_type":"journal-article"},{"id":"pmid:34675810","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/34675810","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Frontiers in pharmacology","raw_type":"Journal Article"},{"id":"pmh:oai:pubmedcentral.nih.gov:8523897","doi":null,"is_oa":true,"landing_page_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC8523897/","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Front Pharmacol","raw_type":"Text"},{"id":"pmh:oai:doaj.org/article:407b43c0a26f43a19b522c1f1855c2df","doi":null,"is_oa":true,"landing_page_url":"https://doaj.org/article/407b43c0a26f43a19b522c1f1855c2df","pdf_url":null,"source":{"id":"https://openalex.org/S4306401280","display_name":"DOAJ (DOAJ: Directory of Open Access Journals)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-sa","license_id":"https://openalex.org/licenses/cc-by-sa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Frontiers in Pharmacology, Vol 12 (2021)","raw_type":"article"},{"id":"pmh:oai:repository.up.ac.za:2263/84309","doi":null,"is_oa":true,"landing_page_url":"http://hdl.handle.net/2263/84309","pdf_url":null,"source":{"id":"https://openalex.org/S4306401870","display_name":"UpSpace Institutional Repository (University of Pretoria)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I69552723","host_organization_name":"University of Pretoria","host_organization_lineage":["https://openalex.org/I69552723"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"","raw_type":"Article"},{"id":"doi:10.60692/fs6fj-ayw92","doi":"https://doi.org/10.60692/fs6fj-ayw92","is_oa":true,"landing_page_url":"https://doi.org/10.60692/fs6fj-ayw92","pdf_url":null,"source":{"id":"https://openalex.org/S7407051682","display_name":"Greater South Information System","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"article-journal"},{"id":"doi:10.60692/ms7d4-0gm09","doi":"https://doi.org/10.60692/ms7d4-0gm09","is_oa":true,"landing_page_url":"https://doi.org/10.60692/ms7d4-0gm09","pdf_url":null,"source":{"id":"https://openalex.org/S7407051682","display_name":"Greater South Information System","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"article-journal"}],"best_oa_location":{"id":"doi:10.3389/fphar.2021.743582","doi":"https://doi.org/10.3389/fphar.2021.743582","is_oa":true,"landing_page_url":"https://doi.org/10.3389/fphar.2021.743582","pdf_url":"https://www.frontiersin.org/articles/10.3389/fphar.2021.743582/pdf","source":{"id":"https://openalex.org/S132108250","display_name":"Frontiers in Pharmacology","issn_l":"1663-9812","issn":["1663-9812"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","ki-jl-1","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320527","host_organization_name":"Frontiers Media","host_organization_lineage":["https://openalex.org/P4310320527"],"host_organization_lineage_names":["Frontiers Media"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Frontiers in Pharmacology","raw_type":"journal-article"},"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W3203612698.pdf","grobid_xml":"https://content.openalex.org/works/W3203612698.grobid-xml"},"referenced_works_count":134,"referenced_works":["https://openalex.org/W1542616270","https://openalex.org/W1555527272","https://openalex.org/W1940241680","https://openalex.org/W1943779301","https://openalex.org/W1970473362","https://openalex.org/W1985106225","https://openalex.org/W2004495270","https://openalex.org/W2015085911","https://openalex.org/W2028376975","https://openalex.org/W2039147606","https://openalex.org/W2069032581","https://openalex.org/W2075703365","https://openalex.org/W2084747579","https://openalex.org/W2097314218","https://openalex.org/W2097995306","https://openalex.org/W2101653483","https://openalex.org/W2103108824","https://openalex.org/W2104347254","https://openalex.org/W2109219217","https://openalex.org/W2113464761","https://openalex.org/W2118471749","https://openalex.org/W2122039897","https://openalex.org/W2125616358","https://openalex.org/W2130829553","https://openalex.org/W2131950300","https://openalex.org/W2134171193","https://openalex.org/W2136672090","https://openalex.org/W2139356364","https://openalex.org/W2140254549","https://openalex.org/W2140875987","https://openalex.org/W2160834915","https://openalex.org/W2165241714","https://openalex.org/W2169794517","https://openalex.org/W2171458854","https://openalex.org/W2222086386","https://openalex.org/W2301851804","https://openalex.org/W2347127875","https://openalex.org/W2413971556","https://openalex.org/W2508205285","https://openalex.org/W2508623887","https://openalex.org/W2511614083","https://openalex.org/W2512217706","https://openalex.org/W2522337762","https://openalex.org/W2540778249","https://openalex.org/W2549414845","https://openalex.org/W2562071695","https://openalex.org/W2567514120","https://openalex.org/W2605157312","https://openalex.org/W2605371223","https://openalex.org/W2614467908","https://openalex.org/W2615312978","https://openalex.org/W2618464237","https://openalex.org/W2618641368","https://openalex.org/W2618943818","https://openalex.org/W2731216694","https://openalex.org/W2736166064","https://openalex.org/W2755659403","https://openalex.org/W2761099324","https://openalex.org/W2765818770","https://openalex.org/W2766709739","https://openalex.org/W2768064013","https://openalex.org/W2771433910","https://openalex.org/W2774533844","https://openalex.org/W2775892985","https://openalex.org/W2791483720","https://openalex.org/W2791926234","https://openalex.org/W2795186863","https://openalex.org/W2799401120","https://openalex.org/W2884259031","https://openalex.org/W2887577080","https://openalex.org/W2889043644","https://openalex.org/W2890296921","https://openalex.org/W2891486030","https://openalex.org/W2893321040","https://openalex.org/W2893824814","https://openalex.org/W2900690448","https://openalex.org/W2902441602","https://openalex.org/W2922793162","https://openalex.org/W2927363814","https://openalex.org/W2929968522","https://openalex.org/W2930693256","https://openalex.org/W2939839404","https://openalex.org/W2947775394","https://openalex.org/W2948303949","https://openalex.org/W2948565764","https://openalex.org/W2954245771","https://openalex.org/W2955040465","https://openalex.org/W2955224282","https://openalex.org/W2958220850","https://openalex.org/W2958936707","https://openalex.org/W2965778028","https://openalex.org/W2966656195","https://openalex.org/W2969658762","https://openalex.org/W2970091829","https://openalex.org/W2971247105","https://openalex.org/W2971634681","https://openalex.org/W2972642313","https://openalex.org/W2973061425","https://openalex.org/W2980042520","https://openalex.org/W2981115487","https://openalex.org/W2981732342","https://openalex.org/W2999931316","https://openalex.org/W3007256753","https://openalex.org/W3007460166","https://openalex.org/W3009099064","https://openalex.org/W3012770963","https://openalex.org/W3016082483","https://openalex.org/W3020819909","https://openalex.org/W3024048796","https://openalex.org/W3024333360","https://openalex.org/W3025765266","https://openalex.org/W3029222366","https://openalex.org/W3034965161","https://openalex.org/W3036508677","https://openalex.org/W3037506839","https://openalex.org/W3043044167","https://openalex.org/W3048922910","https://openalex.org/W3084234809","https://openalex.org/W3084689370","https://openalex.org/W3085588450","https://openalex.org/W3087093127","https://openalex.org/W3090418364","https://openalex.org/W3098386173","https://openalex.org/W3109238634","https://openalex.org/W3118385800","https://openalex.org/W3118404775","https://openalex.org/W3121004297","https://openalex.org/W3122802837","https://openalex.org/W3124034581","https://openalex.org/W3130126061","https://openalex.org/W3133069461","https://openalex.org/W3174077356","https://openalex.org/W4211099881","https://openalex.org/W4313369090"],"related_works":["https://openalex.org/W3197209558","https://openalex.org/W4294689764","https://openalex.org/W4414994614","https://openalex.org/W3093864593","https://openalex.org/W3207653191","https://openalex.org/W7154240683","https://openalex.org/W4285490459","https://openalex.org/W3085588450","https://openalex.org/W4283652020","https://openalex.org/W3114850965"],"abstract_inverted_index":{"The":[0,138,159],"development":[1,160],"of":[2,56,107,126,141,161,188,196,204,213,223,232],"immune":[3,92,108,154],"checkpoint":[4,109],"inhibitors":[5,42,77],"(ICIs)":[6],"has":[7],"revolutionized":[8],"cancer":[9],"treatment,":[10],"with":[11,66,80,135,152,180,184,240],"agents":[12,62,88],"such":[13,244],"as":[14,60,99,226,228,235,245],"nivolumab,":[15],"pembrolizumab,":[16],"and":[17,25,28,53,94,176,193,216,220],"cemiplimab":[18],"targeting":[19,30],"programmed":[20],"cell":[21,169,206],"death":[22],"protein-1":[23],"(PD-1)":[24],"durvalumab,":[26],"avelumab,":[27],"atezolizumab":[29],"PD-ligand":[31],"1":[32],"(PD-L1).":[33],"Ipilimumab":[34],"targets":[35],"cytotoxic":[36],"T":[37,168,191,205],"lymphocyte-associated":[38],"antigen-4":[39],"(CTLA-4).":[40],"These":[41,87],"have":[43],"shown":[44],"remarkable":[45],"efficacy":[46],"in":[47,64,129,174,238],"melanoma,":[48],"lung":[49],"cancer,":[50,52],"urothelial":[51],"a":[54],"variety":[55],"solid":[57],"tumors,":[58],"either":[59,234],"single":[61],"or":[63,124,237],"combination":[65,239],"other":[67,241],"anticancer":[68,242],"modalities.":[69],"Additional":[70],"indications":[71],"are":[72,78],"continuing":[73],"to":[74,85,120,149,166,202],"evolve.":[75],"Checkpoint":[76],"associated":[79,134,151,183],"less":[81],"toxicity":[82],"when":[83],"compared":[84],"chemotherapy.":[86],"enhance":[89],"the":[90,105,122,153,197,211,217,229],"antitumor":[91],"response":[93],"produce":[95],"side-":[96],"effects":[97],"known":[98],"immune-related":[100],"adverse":[101],"events":[102],"(irAEs).":[103],"Although":[104],"incidence":[106],"inhibitor":[110],"pneumonitis":[111,215],"(ICI-Pneumonitis)":[112],"is":[113,118,147,182],"relatively":[114],"low,":[115],"this":[116],"complication":[117],"likely":[119],"cause":[121],"delay":[123],"cessation":[125],"immunotherapy":[127],"and,":[128],"severe":[130],"cases,":[131],"may":[132,163],"be":[133,150,164],"treatment-related":[136],"mortality.":[137],"primary":[139],"mechanism":[140],"ICI-Pneumonitis":[142],"remains":[143],"unclear,":[144],"but":[145],"it":[146],"believed":[148],"dysregulation":[155,203],"caused":[156],"by":[157],"ICIs.":[158],"irAEs":[162],"related":[165],"increased":[167,186],"activity":[170,195],"against":[171],"cross-antigens":[172],"expressed":[173],"tumor":[175],"normal":[177],"tissues.":[178],"Treatment":[179],"ICIs":[181],"an":[185],"number":[187],"activated":[189],"alveolar":[190,214],"cells":[192],"reduced":[194],"anti-inflammatory":[198],"Treg":[199],"phenotype,":[200],"leading":[201],"activity.":[207],"This":[208],"review":[209],"discusses":[210],"pathogenesis":[212],"incidence,":[218],"diagnosis,":[219],"clinical":[221],"management":[222],"pulmonary":[224,230],"toxicity,":[225],"well":[227],"complications":[231],"ICIs,":[233],"monotherapy":[236],"modalities,":[243],"thoracic":[246],"radiotherapy.":[247]},"counts_by_year":[{"year":2026,"cited_by_count":3},{"year":2025,"cited_by_count":15},{"year":2024,"cited_by_count":7},{"year":2023,"cited_by_count":12},{"year":2022,"cited_by_count":5}],"updated_date":"2026-11-12T12:28:57.059296","created_date":"2021-10-11T00:00:00"}